Update from Rejuvenation Biotech – FDA

LIVE UPDATE

James O’Neill (Mithril Capital) on the FDA – The people there like science and curing disease. It is not a people problem, the FDA is structured to make it difficult to move trials forward.

Subscribe on Google News